

DT07 Rec ST/PTO 28 DEC 2004

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant:

YAMAKOSHI, Masaru et al. Conf.:

3292

Appl. No.:

10/509,120

Group:

1645

Filed:

September 28, 2004

Examiner: Unassigned

For:

METHOD FOR DETECTING MILD IMPAIRED

GLUCOSE TOLERANCE OR INSULIN SECRETORY

DEFECT

INFORMATION DISCLOSURE STATEMENT (SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE OR CONCURRENTLY WITH A RULE 1.114 RCE APPLICATION)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 December 28, 2004

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION I.

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449(s), attached hereto.

COPIES (check at least one box) II.

- of cited U.S. patents a. \boxtimes Copies application publications are not included. Copies of foreign patent documents and non-patent literature are included.
- Some or all of the documents listed on the PTOb. 1449 are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

III. CONCISE EXPLANATION OF THE RELEVANCE (check at least one box)

a. DOCUMENTS IN THE ENGLISH LANGUAGE

The patents, publications, or other information listed on the attached PTO 1449 are in the English language and therefore, do not require a statement of relevancy.

b. DOCUMENTS NOT IN THE ENGLISH LANGUAGE

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

A partial English translation is provided for Research Paper of the Suzuken Memorial Foundation, Vol. 17, pp. 249-255; English language Abstracts are provided for JP-2000-298131A and JP 3251976 B2.

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3).

d. OTHER

The following additional information is provided for the Examiner's consideration.

FEES

IV.	\boxtimes	THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b): (check one box)							
	a.		within three months of the filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required. (This section is not to be used with RCE's.)						
	b.		within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required.						
	c.		concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.						
	d.		before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).						
٧.			IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c): ck one box)						
	before the mailing date of a Final Office Action unde C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before mailing date of a Notice of Allowance under 37 C. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).								
	a.		No statement; therefore, a fee in the amount of $\frac{180.00}{\text{or}}$ as required by 37 C.F.R. § 1.17(p).						
	b.		See the statement below. No fee is required.						



VI. STATEMENT UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby states that

- a.
 each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this IDS; or
- each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- c. no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS.
- Some of the items of information were cited in a d. \Box communication from a foreign Patent Office. As to information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Office Patent in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

VII. PAYMENT OF FEES (check one box)

- A check in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p) is enclosed for the above-identified fee.
- Please charge Deposit Account No. 02-2448 in the amount required by 37 C.F.R. § 1.17(p) for the aboveindicated fee. This paper is submitted in triplicate.
- No fee is required. \boxtimes

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

nd C. Stewart,

P.O. Box 747

Falls Church, VA 22040-0747 RCS:bmp (703) 205-8000 1516-0126PUS1

Attachment(s): X PTO-1449 Documents Foreign Search Report Fee Other:

DE 28 2004 E

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

ATTY. DOCKET NO. 1516-0126PUS1

APPLICATION NO. 10/509,120

APPLICANT

YAMAKOSHI, Masaru et al.

US 5,356,790 A 1994-10-18 Ueda et al. FOREIGN PATENT DOCUMENTS Office DOCUMENT Kind DATE COUNTRY CLASS SUB CLASS TRANSLATION			LCATION						
DOCUMENT NUMBER Kind DATE NAME CLASS SUB FILING DATE US 5,356,790 A 1994-10-18 Ueda et al. FOREIGN PATENT DOCUMENTS Office DOCUMENT NUMBER Kind DATE COUNTRY CLASS SUB CLASS VIS CLASS		(Use several sheets	if necessar	ry)		2004			
US 5,356,790 A 1994-10-18 Ueda et al.			U	.S. PATENT D	OCUMENTS				
FOREIGN PATENT DOCUMENTS Office DOCUMENT NUMBER Kind DATE COUNTRY CLASS TRANSIATION (LASS) TOWNSTATION (LASS) (LASS) (LASS) (LASS) TOWNSTATION (LASS) (LAS	EXAMINER DOC	CUMENT NUMBER	Kind	DATE	NAME	CLASS		FILING DATE IF APPROPRIATE	
Office DOCUMENT Kind DATE COUNTRY CLASS SUB CLASS NUMBER PCT WO 99/60406 A1 1999-11-25 PCT JP 2000-298131 A 2000-10-24 JAPAN Abs. JP 3251976 B2 2002-01-28 JAPAN Abs. OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazi streal, serial, s	U	US 5,356,790		1994-10-18	Ueda et al.			<u> </u>	
Office DOCUMENT Kind DATE COUNTRY CLASS SUB CLASS NUMBER PCT WO 99/60406 A1 1999-11-25 PCT JP 2000-298131 A 2000-10-24 JAPAN Abs. JP 3251976 B2 2002-01-28 JAPAN Abs. OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazi streal, serial, s									
PCT WO 99/60406 Al 1999-11-25 PCT JP 2000-298131 A 2000-10-24 JAPAN Abs. JP 3251976 B2 2002-01-28 JAPAN Abs. DTHER DOCUMENTS (Include Name of the author (in CAPITAL ENTERS), title of the article (when appropriate), title of the item (book, magesi streal, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. Kennington, A. et al., The New England Journal of Medicine, Vol. 323, No. 6, pp. 3738; (1990) Suzuki, S. et al., Diabetes Care, Vol. 17, No. 12, pp. 1465-1468 (1994) Research Papers of the Suzuken Memorial Foundation, Vol. 17, pp. 249-255; Ikagaku On Kenkyu Zaidan Kenkyu Hokoku (2000), Volume date 1998. Dolhofer, R. et al., J. Clin.Chem.Clin.Biochem., Vol. 25, No. 10, pp. 733-736 (1987) Kouzuma, T. et al., Clinica Chimica Acta 312, pp. 143-151 (2001)			FOR	EIGN PATENT	DOCUMENTS	L	<u>. </u>		
JP 2000-298131 A 2000-10-24 JAPAN Abs. JP 3251976 B2 2002-01-28 JAPAN Abs. OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magasi stream, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. Kennington, A. et al., The New England Journal of Medicine, Vol. 323, No. 6, pp. 37. 378; (1990) Suzuki, S. et al., Diabetes Care, Vol. 17, No. 12, pp. 1465-1468 (1994) Research Papers of the Suzuken Memorial Foundation, Vol. 17, pp. 249-255; Ikagaku Otkenkyu Zaidan Kenkyu Hokoku (2000), Volume date 1998. Dolhofer, R. et al., J. Clin.Chem.Clin.Biochem., Vol. 25, No. 10, pp. 733-736 (1987) Kouzuma, T. et al., Clinica Chimica Acta 312, pp. 143-151 (2001)	Offic		Kind	DATE	COUNTRY	CLASS			ATION
JP 3251976 B2 2002-01-28 JAPAN Abs. OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazi real, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. Kennington, A. et al., The New England Journal of Medicine, Vol. 323, No. 6, pp. 3738; (1990) Suzuki, S. et al., Diabetes Care, Vol. 17, No. 12, pp. 1465-1468 (1994) Research Papers of the Suzuken Memorial Foundation, Vol. 17, pp. 249-255; Ikagaku On Kenkyu Zaidan Kenkyu Hokoku (2000), Volume date 1998. Dolhofer, R. et al., J. Clin.Chem.Clin.Biochem., Vol. 25, No. 10, pp. 733-736 (1987) Kouzuma, T. et al., Clinica Chimica Acta 312, pp. 143-151 (2001)	PCT	WO 99/60406	A1	1999-11-25	PCT				
DTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazi arral, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. Kennington, A. et al., The New England Journal of Medicine, Vol. 323, No. 6, pp. 37: 378; (1990) Suzuki, S. et al., Diabetes Care, Vol. 17, No. 12, pp. 1465-1468 (1994) Research Papers of the Suzuken Memorial Foundation, Vol. 17, pp. 249-255; Ikagaku Oy Kenkyu Zaidan Kenkyu Hokoku (2000), Volume date 1998. Dolhofer, R. et al., J. Clin.Chem.Clin.Biochem., Vol. 25, No. 10, pp. 733-736 (1987) Kouzuma, T. et al., Clinica Chimica Acta 312, pp. 143-151 (2001)	JP	2000-298131	A	2000-10-24	JAPAN			Abs.	
Kennington, A. et al., The New England Journal of Medicine, Vol. 323, No. 6, pp. 373, 378; (1990) Suzuki, S. et al., Diabetes Care, Vol. 17, No. 12, pp. 1465-1468 (1994) Research Papers of the Suzuken Memorial Foundation, Vol. 17, pp. 249-255; Ikagaku Orkenkyu Zaidan Kenkyu Hokoku (2000), Volume date 1998. Dolhofer, R. et al., J. Clin.Chem.Clin.Biochem., Vol. 25, No. 10, pp. 733-736 (1987) Kouzuma, T. et al., Clinica Chimica Acta 312, pp. 143-151 (2001)	JP	3251976	B2	2002-01-28	JAPAN			Abs.	
Kennington, A. et al., The New England Journal of Medicine, Vol. 323, No. 6, pp. 373, 378; (1990) Suzuki, S. et al., Diabetes Care, Vol. 17, No. 12, pp. 1465-1468 (1994) Research Papers of the Suzuken Memorial Foundation, Vol. 17, pp. 249-255; Ikagaku Orkenkyu Zaidan Kenkyu Hokoku (2000), Volume date 1998. Dolhofer, R. et al., J. Clin.Chem.Clin.Biochem., Vol. 25, No. 10, pp. 733-736 (1987) Kouzuma, T. et al., Clinica Chimica Acta 312, pp. 143-151 (2001)									
Kennington, A. et al., The New England Journal of Medicine, Vol. 323, No. 6, pp. 373, 378; (1990) Suzuki, S. et al., Diabetes Care, Vol. 17, No. 12, pp. 1465-1468 (1994) Research Papers of the Suzuken Memorial Foundation, Vol. 17, pp. 249-255; Ikagaku Orkenkyu Zaidan Kenkyu Hokoku (2000), Volume date 1998. Dolhofer, R. et al., J. Clin.Chem.Clin.Biochem., Vol. 25, No. 10, pp. 733-736 (1987) Kouzuma, T. et al., Clinica Chimica Acta 312, pp. 143-151 (2001)	195								
Kennington, A. et al., The New England Journal of Medicine, Vol. 323, No. 6, pp. 373, 378; (1990) Suzuki, S. et al., Diabetes Care, Vol. 17, No. 12, pp. 1465-1468 (1994) Research Papers of the Suzuken Memorial Foundation, Vol. 17, pp. 249-255; Ikagaku Orkenkyu Zaidan Kenkyu Hokoku (2000), Volume date 1998. Dolhofer, R. et al., J. Clin.Chem.Clin.Biochem., Vol. 25, No. 10, pp. 733-736 (1987) Kouzuma, T. et al., Clinica Chimica Acta 312, pp. 143-151 (2001)									
Research Papers of the Suzuken Memorial Foundation, Vol. 17, pp. 249-255; Ikagaku Oy Kenkyu Zaidan Kenkyu Hokoku (2000), Volume date 1998. Dolhofer, R. et al., J. Clin.Chem.Clin.Biochem., Vol. 25, No. 10, pp. 733-736 (1987) Kouzuma, T. et al., Clinica Chimica Acta 312, pp. 143-151 (2001)	Kenn:	ington, A. et al	., The I	Wew England Jou	rnal of Medicine,	Vol. 32	3, No.		
Kenkyu Zaidan Kenkyu Hokoku (2000), Volume date 1998. Dolhofer, R. et al., J. Clin.Chem.Clin.Biochem., Vol. 25, No. 10, pp. 733-736 (1987) Kouzuma, T. et al., Clinica Chimica Acta 312, pp. 143-151 (2001)		,			22, pp. 2000		,		
Kouzuma, T. et al., Clinica Chimica Acta 312, pp. 143-151 (2001)		arch Papers of t	he Suzul Hokoku	ken Memorial Fo (2000), Volume	undation, Vol. 17, date 1998.	pp. 24	9-255;	Ikagakı	Oy د
·	Resea Kenky	yu zaidan kenkyu							
AMINER DATE CONSIDERED	Kenky	-			chem., Vol. 25, No	. 10, p	p. 733-	736 (19	987)
AMINER DATE CONSIDERED	Dolho	ofer, R. et al.,	J. Cli	n.Chem.Clin.Bio			p. 733-	736 (19	987)
	Dolho	ofer, R. et al.,	J. Cli	n.Chem.Clin.Bio			p. 733-	736 (19	987)

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.